Biogen Inc. has exercised an option to purchase additional shares in Samsung Bioepis Co. Ltd., a joint venture established in 2012 by Samsung BioLogics and the US firm, in a move that will raise its stake to nearly 50% and allow Biogen to jointly run the biosimilars venture.
Under the terms of the original joint venture agreement, Biogen will pay Samsung BioLogics about $700m for the option shares, increasing Biogen’s ownership in Samsung Bioepis from about 5.4% to about 49.9%